UNSPSC 51411704: Ethaverine

This classification denotes a calcium channel blocker and antispasmotic agent with the molecular formula C24H29NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2H2HC19DYZ, chemically known as 6,7-diethoxy-1-(3, 4-diethoxybenzyl)isoquinoline hydrochloride but generally known as ethaverine, which bears US NIH Compound Identifier 3280. European Medicines Agency schedules Ethaverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07272MIG. The term ETHAVERINE is an International Non-Proprietary Name.

UNSPSC 51411704 Ethaverine is a Commodity code representing pharmaceutical active pharmaceutical ingredients and finished medications procured directly by state and local health systems, emergency services, and multi-state cooperative purchasing alliances. State and local governments purchase ethaverine and related drugs under this code primarily as components of emergency life support medication supplies, pharmacy benefit program inventories, and general pharmaceutical stockpiles distributed through authorized wholesalers and direct-to-manufacturer channels. Issuing bodies include municipal fire and rescue departments (Tampa Fire Rescue through the City of Tampa), state health and human services agencies (Texas HHS Commission), and cooperative purchasing organizations serving multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance administering on behalf of Minnesota Department of Administration and participating states including Oregon).

Recent activity spans Florida, Texas, and the Upper Midwest. The City of Tampa's Purchasing Department issued IFB 26P00188 on April 24, 2026, for Advanced Life Support Medications including labetalol, epinephrine, adenosine, and diltiazem for Tampa Fire Rescue, with bids due April 8, 2026 and an estimated contract value of $40,000.00; the solicitation carried a 5 percent SLBE bid discount and required nine-month minimum expiration dates with ten-calendar-day delivery. The Texas HHS Commission issued RFI HHS0017013 in late March 2026 to solicit vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, exploring direct contracting models outside traditional PBM and GPO channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with proposals due March 26, 2026, price weighted at 75 percent, and a two-year contract term effective July 1, 2026.